About the role
CEPI is looking for an Epidemiologist with a background in early warning and epidemic/pandemic preparedness to join our growing Research and Development Department and more specifically, the Epidemiology function. The Epidemiology function supports CEPI, its partners, and stakeholders by bridging key epidemiological knowledge gaps for vaccine development. This will be achieved by: 1) identifying, characterizing, and addressing epidemiological knowledge gaps throughout vaccine development; 2) conceptualizing epidemiological activities to deliver high impact epidemiological data directly addressing barriers that may impair rapid and equitable vaccine development and access, and 3) providing upstream strategic input and epidemic intelligence to inform pathogen prioritization and vaccine development pathways. The Epidemiology function therefore ensures that scientific advice, innovation on vaccine evaluation and public health needs are integrated with product development. Given the cross-functional nature of the epidemiological activities across the vaccine development value chain, the Epidemiology function works in close collaboration with the other R&D functions.
The key purpose of the role is to provide support to conduct threat assessments for CEPI core priority pathogens and to detect potential Disease X emergencies to initiate R&D activities. We are looking for candidates that are motivated by CEPI’s mission, have an advanced degree (Masters) in Epidemiology or relevant discipline (Public Health), with three or more years’ experience conducting epidemiological research particularly related to real-time active disease surveillance.
This role reports to the Head of Epidemiology. We are primarily looking for candidates who will be based in Oslo, Norway. We will, however, also consider candidates who could be based London, UK.
In CEPI we strive for diverse thinking, and we want diverse pools of candidates for all our vacancies. We work for an inclusive working environment where each employee can contribute and grow.
Responsibilities
Education, Experience and Competence
Essential:
Preferred:
Travel and Location Requirements
What we can offer you
How to apply
Launched in 2017, the Coalition for Epidemic Preparedness Innovations (CEPI) is an international coalition of governments, academic, philanthropic, private, public, and intergovernmental institutions whose vision is to create a world in which epidemics and pandemics are no longer a threat to humanity. Our mission is to to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI has played a central role in the global response to COVID-19, creating the world’s largest portfolio of COVID-19 vaccines – two of which are already saving lives around the world - and co-leading COVAX which is delivering equitable access to COVID-19 vaccines to participating economies worldwide. During this period, CEPI has also overseen several scientific breakthroughs in developing vaccines against other infectious diseases, including the first phase 3 trial of a Chikungunya vaccine and the advancement of the first ever Nipah virus and Lassa virus vaccines into phase 1 clinical trials.
There is an urgent need to do more to mitigate the immediate threat of COVID-19 variants and to prepare now for the next pandemic. As COVID-19 has demonstrated, emerging infectious diseases represent an existential threat to our way of life. COVID-19 is not the first pandemic of the 21st century, and unless we act now, we can be sure that it will not be the last. But unlike some of the other big threats that humanity faces, we have the tools to systematically reduce and even eliminate the risk of future pandemics. It is vital that we capitalise on the rare alignment of political will, practical experience, and technical and scientific progress emerging from the pandemic to prevent such devastation happening again. CEPI has a US$3.5bn five-year plan to tackle the risk of pandemics and epidemics, potentially averting millions of deaths and trillions of dollars in economic damage. This plan will urgently address the immediate threat of COVID-19 variants so we can bring the COVID-19 pandemic to an end; and enable us to prepare now for future threats. This includes our aim to reduce the vaccine development timeline to a 100-day ‘moonshot’ target and to advance the development of broadly protective vaccines that can protect against COVID-19 and its variants, as well as other known or novel coronaviruses.
CEPI is organised as a not-for-profit association under Norwegian Law and has offices in Oslo (HQ), London, and Washington, DC.
More details about CEPI and our mission can be found on our website: www.cepi.net